Anteris Technologies fields "excellent" 30-day haemodynamic results for DurAVR™ THV in US early feasibility study
Anteris Technologies Ltd (ASX:AVR, OTC:AMEUF) has released 30-day data described as "excellent" from its US early feasibility study (EFS) for the DurAVR™...
Source: proactiveinvestors.com